Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.

Stangelberger, Anton; Schally, Andrew V; Rick, Ferenc G; Varga, Jozsef L; Baker, Benjamin; Zarandi, Marta; Halmos, Gabor

Stangelberger, Anton; Schally, Andrew V; Rick, Ferenc G; Varga, Jozsef L; Baker, Benjamin; Zarandi, Marta; Halmos, Gabor.

Affiliation

Stangelberger A; Department of Urology, Landesklinikum Baden, Baden, Austria.

Prostate ; 72(5): 555-65, 2012 Apr.

Article in En | MEDLINE | ID: mdl-21796649

Subject(s)

Adenocarcinoma/drug therapy; Antineoplastic Agents/pharmacology; Mutant Proteins/genetics; Prostatic Neoplasms/drug therapy; Proto-Oncogene Proteins p21(ras)/genetics; Sermorelin/analogs & derivatives; Tumor Suppressor Protein p53/genetics; Adenocarcinoma/genetics; Adenocarcinoma/metabolism; Animals; Apoptosis/drug effects; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Nude; Mutant Proteins/metabolism; Neoplasm Transplantation; Neoplasms, Hormone-Dependent/drug therapy; Neoplasms, Hormone-Dependent/genetics; Neoplasms, Hormone-Dependent/metabolism; Prostatic Neoplasms/genetics; Prostatic Neoplasms/metabolism; Proto-Oncogene Proteins p21(ras)/metabolism; Sermorelin/pharmacology; Tumor Suppressor Protein p53/metabolism; Up-Regulation

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Adenocarcinoma / Tumor Suppressor Protein p53 / Proto-Oncogene Proteins p21(ras) / Sermorelin / Mutant Proteins / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans / Male Language: En Journal: Prostate Year: 2012 Document type: Article Affiliation country: Austria Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google